• MyriadPro Login
  • Register
  • English
  • Français
  • Deutsch
  • Italiano
Myriad Logo
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • Newsletter signup
      • News center
      • Press releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • Newsletter signup
      • News center
      • Press releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form

News Center

News Center
  • Category
    • All
    • Patients
    • Pipeline
    • Products
    • Providers

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

December 30, 2019

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreati...

Continue Reading

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

December 14, 2019

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes New Clinical Validation S...

Continue Reading

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

December 4, 2019

Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening SALT LAKE CITY, Dec. 04, 2019 (...

Continue Reading

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

December 3, 2019

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- M...

Continue Reading

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis

November 20, 2019

The American College of Rheumatology Includes the Vectra® Test in New Recommendations on Disease Activity Measures for Rheumatoid Arthritis SALT LAKE CITY, Nov...

Continue Reading

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening

November 11, 2019

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy Clinical Study Shows Prequel...

Continue Reading

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis

November 9, 2019

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis Vectra Test Predicts Radiographic Progression an...

Continue Reading

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting

November 1, 2019

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- M...

Continue Reading

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting

October 28, 2019

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myr...

Continue Reading

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

October 8, 2019

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad G...

Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Myriad Logo

Health. Illuminated.

  • Contact Us
  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.